Suicidal Behavior is Attenuated in Patientis with Multiple Sclerosis by Treatment with Electromagnetic Fields

International Journal of Neuroscience

Volumn 87, Issue 42006, 1996, Pages 5-15

  Sandyk, Reuven ^a,b  

^a NeuroCummunication Res Laboratories   (United States)

^b TOURO COLLEGE   (United States)

Author keywords

electromagnetic fields; melatonin; Multiple sclerosis; pineal gland; serotonin; suicidal behavior

Indexed keywords

MELATONIN;

ADULT; ARTICLE; BLOOD; CASE REPORT; CIRCADIAN RHYTHM; DEPRESSION; ELECTROMAGNETIC FIELD; FEMALE; HUMAN; MIDDLE AGED; MULTIPLE SCLEROSIS; PINEAL BODY; PSYCHOLOGICAL ASPECT; SECRETION; SUICIDE;

ADULT; CIRCADIAN RHYTHM; DEPRESSIVE DISORDER; ELECTROMAGNETIC FIELDS; FEMALE; HUMANS; MELATONIN; MIDDLE AGED; MULTIPLE SCLEROSIS; PINEAL GLAND; SUICIDE;

EID: 0030268515     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207459608990750     Document Type: Article

References (101)

1. Aldegunde M., Miguez I., Veira J. Effects of pinealectomy on regional brain serotonin metabolism. International Journal of Neuroscience 1985; 26: 9 – 13
2. Arendt J. Melatonin: a new probe in psychiatric investigations?. British Journal of Psychiatry 1989; 155: 585 – 590
3. Arendt J., Wirz-Justice A., Bardtke J. Annual rhythm of serum melatonin in man. Neuroscience Letters 1977; 7: 327 – 330
4. Asberg M., Traskman L., Thoren P. 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor?. Archives of General Psychiatry 1976; 33: 1193 – 1197
5. Baldwin M. V. A clinico-experimental investigation into the psychologic aspects of multiple sclerosis. Journal of Nervous and Mental Disease 1952; 115: 299 – 342
6. Baretz R. M., Stephenson G. R. Emotional responses to multiple sclerosis. Psychosomatics 1981; 22: 117 – 127
7. Bawin S. M., Adey W. R. Sensitivity of calcium binding in cerebral tissue to weak environmental electric fields oscillating at low frequency. Proceedings of the National Academy of Sciences, USA, 1976; 1999 – 2003, 73
8. Beek-Friis J., Von Resen D., Kjellman B. F., Ljunggren J. G., Wetterberg L. Melatonin in relation to body measures, sex, age, season and use of drugs in patients with major affective disorders and healthy subjects. Psychoneuroendocrinology 1984; 9: 261 – 277
9. Bignami A., Gherardi D., Gallo G. Sclerosi a placche acuta a localizzazione ipotalamica con sintomatologia psichia di tipo malinconcio. Rivista Neurologico 1961; 31: 240 – 268
10. Blackman C. F. Stimulation of brain tissue in vitro by extremely low frequency, low intensity, sinusoidal electromagnetic fields. Electromagnetic fields and neurobehavioral function, M. E. O'Connor, R. H. Lovely. Alan R. Liss, New York 1988
11. Cardinali D. P. Changes in hypothalamic neurotransmitter uptake following pinealectomy, superior cervical ganglionectomy or melatonin administration to rats. Neuroendocrinology 1975; 19: 91 – 95
12. Chance W. T., Grossman C. J., Newrock R., Bovin G., Yerian S., Schmitt G., Mendenhall C. Effects of electromagnetic fields and gender on neurotransmitters and amino acids in rats. Physiology & Behavior 1995; 58: 743 – 748
13. Charcot J. M. Lectures on Diseases of the Nervous System, G. Sigerson. New Sydenham Society, London 1877, Translated from the French by
14. Claveria L. E., Curzon G., Harrison M. J. G., Kantamaneni B. D. Amine metabolites in the cerebrospinal fluid of patients with disseminated sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 1974; 37: 715 – 718
15. Cottrell S. S., Wilson S. A. K. The affective symptomatology of disseminated sclerosis. Journal of Neurology and Psychopathology 1926; 25: 1 – 30
16. Cremieux A., Alliez J., Tonga M., Pache R. Sclerose en plaques a debut par troubles mentaux: Etude Anatomo-Clinique. Revue Neurologique (Paris) 1959; 101: 45 – 51
17. Dolos N. P., Rabins P. V., Brooks B. R., O'Donnell P. Disease activity and emotional state in multiple sclerosis. Annals of Neurology 1983; 13: 573 – 577
18. Demisch K., Demisch L., Nickelson T., Ruth R. The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increases following fluvoxamine. Journal of Neural Transmission 1987; 68: 257 – 270
19. Dixey R., Rein G. 3H-noradrenaline release potentiated in a clonal nerve cell line by low-intensity pulsed magnetic field. Nature 1982; 296: 253 – 256
20. Durkheim E. Suicide. Free Press, Glencoe, IL 1951
21. Fischman H. R. Multiple sclerosis: a two stage process?. American Journal of Epidemiology 1981; 114: 244 – 252
22. Garfield D. A. S. Multiple sclerosis and affective disorder: 2 case reports of mania with psychosis. Psychotherapy & Psychosomatics 1985; 44: 25 – 33
23. Honer W. G., Hurwitz T., Li D. K. B., Palmer M., Paty D. W. Temporal lobe involvement in multiple sclerosis patients with psychiatric disorders. Archives of Neurology 1987; 44: 187 – 190
24. Hyyppa M. T., Jolma T., Riekkinen P., Rinne U. K. Effects of L-tryptophan on central indoleamine metabolism and short-lasting neurologic disturbances in multiple sclerosis. Journal of Neural Transmission 1975; 37: 297 – 304
25. Jaffe R. A., Laszewski B. L., Carr D. B., Phillips R. D. Chronic exposure to a 60-Hz electric field: effects on synaptic transmission and peripheral nerve function in the rat. Bioelectromagnetics 1980; 1: 131 – 147
26. Jankovic B. D., Isakovic K., Petrovic S. Effect of pinealectomy on immune reactions in the rat. Immunology 1970; 18: 1 – 5
27. Joffe R. T., Lippert G. P., Gray T. A. Mood disorder and multiple sclerosis. Archives of Neurology 1987; 44: 376 – 378
28. Johansson B., Ross B. E. 5-hydroxyindoleacetic acid and homovanillic acid in CSF of patients with neurological disease. European Neurology 1977; 11: 37 – 45
29. Kahana E., Leibowitz W., Alter. Cerebral multiple sclerosis. Neurology 1971; 21: 1179 – 1185
30. Kellner C. H., Davenport Y., Post R. M., Ross R. J. Rapidly cycling bipolar disorder and multiple sclerosis. American Journal of Psychiatry 1984; 141: 112 – 113
31. Korpi E. R., Kleinman J. E., Goodman S. I., Phillips I., DeLisi L. E., Linnoila M., Wyatt R. J. Serotonin and 5-hydroxyindoleacetic acid in brains of suicide victims. Comparison in chronic schizophrenic patients with suicide as cause of death. Archives of General Psychiatry 1986; 43: 594 – 600
32. Kurtzke J. F. On the time of onset in multiple sclerosis. Acta Neurologica Scandinavica 1965; 44: 140 – 158
33. Kurtzke J. F., Hyllested K. Multiple sclerosis in the Faroe Islands: I. clinical and epidemiological features. Annals of Neurology 1979; 5: 6 – 21
34. Leibowitz U., Kahana E., Jacobson S. G., Alter M. The cause of death in multiple sclerosis. Progress in multiple sclerosis, U. Leibowits. Academic Press, New York 1972; 196 – 209
35. Lerchl A., Nonaka K. O., Stokkan K. A., Reiter R. J. Marked rapid alterations in nocturnal pineal serotonin metabolism in mice and rats exposed to weak intermittent magnetic fields. Biochemical and Biophysical Research Communications 1990; 169: 102 – 108
36. Lerchl A., Nonaka K. O., Reiter R. Pineal gland “magnetosensitivity” to static magnetic fields is a consequence of induced electric currents (eddy currents). Journal of Pineal Research 1991; 10: 109 – 116
37. Lublin F. D., Whitaker J. N., Eidelman B. H., Miller A. E., Arnason B. G. W., Burks J. S. Management of patients receiving interferon beta-1b for multiple sclerosis. Neurology 1996; 46: 12 – 18
38. MacKenzie T. B., Popkin M. K. Suicide in the medicated patient. International Journal of Psychiatric Medicine 1987; 17: 3 – 22
39. Maestroni G. J. M., Conti A., Pierpaoli W. The pineal gland and the circadian, opiatergic, immunoregulatory role of melatonin. Annals of the New York Academy of Science 1987; 496: 67 – 77
40. Mann J. J., McBride P. A., Stanley M. Post-mortem monoamine receptor and enzyme studies in suicide. Annals of the New York Academy of Sciences 1986; 487: 114 – 121
41. Masterson G. Monthly and seasonal variation in parasuicide. A sex difference. British Journal of Psychiatry 1991; 158: 155 – 157
42. McIvor G. P., Riklan M., Reznikoff M. Depression in multiple sclerosis as a function of length and severity of illness, age, remission, and perceived social support. Journal of Clinical Psychology 1984; 40: 1028 – 1033
43. Miguez J. M., Martin F., Aldegunde M. Differential effects of pinealectomy on amygdala and hippocampus serotonin metabolism. Journal of Pineal Research 1991a; 10: 100 – 103
44. Miguez J. M., Martin F., Aldegunde M. Long-term pinealectomy alters hypothalamic serotonin metabolism in the rat. Journal of Pineal Research 1991b; 11: 75 – 79
45. Miguez J. M., Martin F. J., Aldegunde M. Effects of single doses and daily melatonin treatments on serotonin metabolism in rat brain regions. Journal of Pineal Research 1994; 17: 170 – 176
46. Miledi R. Transmitter release induced by injection of calcium ions into nerve terminals. Proceedings of the Royal Society of Biological Sciences. 1973; 421 – 428, 183
47. Minden S. L., Schiffer R. B. Affective disorders in multiple sclerosis. Review and recommendations for clinical research. Archives of Neurology 1990; 47: 98 – 104
48. Minden S. L., Orav J., Reich P. Depression in multiple sclerosis. General Hospital Psychiatry 1987; 9: 426 – 434
49. Monaco F., Fumero S., Mondino A., Mutani R. Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry 1979; 42: 640 – 641
50. Muehlbauer H. D. Human aggression and the role of central serotonin. Pharmacopsychiatrie 1985; 18: 218 – 221
51. Mulder D. W. Psychosis with brain tumors and other neurologic disorders. American handbook of psychiatry, S. Arieti. Basis Books, New York 1959; 457
52. Neilley L. K., Goodin D. S., Goodkin D. E., Hauser S. L. Side effect profile of interferon beta-1b in MS: results from and open label trial. Neurology 1996; 46: 552 – 554
53. Ninan P. T., van Kammen D. P., Scheinin M., Linnoila M., Bunney W. E., Goodwin F. K. CSF 5-hydroxy indoleacetic acid levels in suicidal schizophrenic patients. American Journal of Psychiatry 1984; 141: 566 – 569
54. Parker G., Walter S. Seasonal variation in depressive disorders and suicidal deaths in New South Wales. British Journal of Psychiatry 1982; 140: 626 – 632
55. Pierpaoli W., Maestroni G. J. M. Neuroimmunomodulation: some recent views and findings. International Journal of Neuroscience 1988; 39: 165 – 175
56. Pokomy A. D. Myths about suicide. Suicidal behaviors, H. L. P. Resnick. Little Brown and Company, Boston 1968
57. Rao S. M., Leo G. J. Mood disorder in multiple sclerosis. Archives of Neurology 1988; 45: 247 – 248
58. Rao S. M., Hammeke T. A., McQuillen M. P., Khatri B. O., Lloyd D. Memory disturbance in chronic progressive multiple sclerosis. Archives of Neurology 1984; 41: 625 – 631
59. Rao S. M., Huber S. J., Bornstein R. A. Emotional changes with multiple sclerosis and Parkinson's disease. Journal of Consulting and Clinical Psychology 1992; 60: 369 – 378
60. Reichardt L. F., Kelly R. B. A molecular description of nerve terminal function. Annual Review of Biochemistry 1983; 52: 871 – 926
61. Reiter R. J. Static and extrtemely low frequency electromagnetic field exposure: reported effects on the circadian production of melatonin. Journal of Cellular Biochemistry 1993; 51: 394 – 403
62. Reiter R. J., Richardson B. A. Magnetic fields effects on pineal indoleamine metabolism and possible biological consequences. FASEB Journal 1992; 6: 2283 – 2287
63. Rella W., Lapin V. Immunocompetence of pinealectomized and simulateneously pinealectomized and thymectomized rats. Oncology 1976; 33: 3 – 6
64. Rosen A. D., Lubowsky J. Magnetic field influence on central nervous system function. Experimental Neurology 1987; 95: 679 – 687
65. Roszman T. L., Jackson J. C., Cross R. J., Titus M. J., Markesbery W. R., Brooks W. H. Neuroanatomic and neurotransmitter influences on immune function. Journal of Immunology 1985; 135: 769S – 772S
66. Roy A., DeJong J., Linnoila M. Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study. Archives of General Psychiatry 1989; 46: 606 – 612
67. Sadovnick A. D., Eisen K., Ebers G. C., Paty D. W. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41: 1193 – 1196
68. Sandyk R. Successful treatment of multiple sclerosis with magnetic fields. International Journal of Neuroscience 1992a; 66: 237 – 250
69. Sandyk R. The pineal gland and multiple sclerosis. (Editorial). International Journal of Neuroscience 1992b; 63: 206 – 215
70. Sandyk R. Multiple sclerosis: The role of puberty and the pineal gland in its pathogenesis. International Journal of Neuroscience 1993; 68: 209 – 225
71. Sandyk R. Rapid normalization of visual evoked potentials by picotesla range magnetic fields in chronic progressive multiple sclerosis. International Journal of Neuroscience 1994; 77: 243 – 259
72. Sandyk R. Chronic relapsing multiple sclerosis: a case of rapid recovery by application of weak electromagnetic fields. International Journal of Neuroscience 1995a; 82: 223 – 242
73. Sandyk R. Long term beneficial effects of weak electromagnetic fields in multiple sclerosis. International Journal of Neuroscience 1995b; 83: 45 – 57
74. Sandyk R., Awerbuch G. I. Nocturnal plasma melatonin and alpha-melanocyte stimulating hormone levels during exacerbation of multiple sclerosis. International Journal of Neuroscience 1992; 67: 173 – 186
75. Sandyk R., Awerbuch G. I. Nocturnal melatonin secretion in suicidal patients with multiple sclerosis. International Journal of Neuroscience 1993a; 71: 173 – 182
76. Sandyk R., Awerbuch G. I. Nocturnal melatonin secretion in multiple sclerosis patients with affective disorders. International Journal of Neuroscience 1993b; 68: 227 – 240
77. Sandyk R., Derpapas K. Magnetic fields normalize visual and brainstem auditory evoked potentials in multiple sclerosis. International Journal of Neuroscience 1993a; 70: 97 – 105
78. Sandyk R., Iacono R. P. Resolution of longstanding symptoms of multiple sclerosis by application of picotesla range magnetic fields. International Journal of Neuroscience 1993; 70: 255 – 269
79. Sandyk R., Iacono R. P. Improvement by picotesla magnetic fields of preceptual-motor performance in a patient with chronic progressive multiple sclerosis. International Journal of Neuroscience 1994; 78: 53 – 66
80. Sandyk R., Dann L. C. Weak electromagnetic fields attenuate tremor in multiple sclerosis. International Journal of Neuroscience 1994; 79: 199 – 212
81. Sandyk R., Dann L. C. Resolution of Lhermitte's sign in multiple sclerosis by treatment with weak electromagnetic fields. International Journal of Neuroscience 1995; 81: 215 – 224
82. Schiffer R. B. The spectrum of depression in multiple sclerosis. An approach for clinical management. Archives of Neurology 1987; 44: 596 – 599
83. Schiffer R. B., Babigian H. M. Behavioral disorders in multiple sclerosis, temporal lobe epilepsy, and amyotrophic lateral sclerosis: an epidemiologic study. Archives of Neurology 1984; 41: 1067 – 1069
84. Schiffer R. B., Wineman N. M., Weitkamp L. R. Association between bipolart affective disorder and multiple sclerosis. American Journal of Psychiatry 1986; 143: 94 – 95
85. Sharma H. S., Dey P. K. Probable involvement of 5-hydroxytryptamine in increased permeability of blood-brain barrier under heat stress in young rats. Neuropharmacology 1986; 25: 161 – 167
86. Shaw D. M., Camps F. E., Eccleston E. G. 5-hydroxytryptamine in the hindbrain of depressive suicides. British Journal of Psychiatry 1967; 113: 1407 – 1411
87. Smith C. R., Scheinberg L. C. Clinical features of multiple sclerosis. Seminars in Neurology 1985; 5: 85 – 93
88. Sonninen V., Riekkinen P., Rinne U. K. Acid monoamine metabolites in cerebrospinal fluid in multiple sclerosis. Neurology 1973; 23: 760 – 763
89. Stanley M., Brown G. M. Melatonin levels are reduced in the pineal glands of suicide victims. Psychopharmacology Bulletin 1988; 23: 484 – 488
90. Sugden D., Morris R. D. Changes in regional brain levels of tryptophan, 5-hydroxytryptamine, 5-hydroxyindoleacetic acid, dopamine and noradrenaline after pinealectomy in the rat. Journal of Neurochemistry 1979; 32: 1593 – 1595
91. Surridge D. An investigation into some psychiatric aspects of multiple sclerosis. British Journal of Psychiatry 1969; 115: 749 – 764
92. Tabaddor K., Wolfson L. I., Sharpless N. S. Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders. Neurology 1978; 28: 1249 – 1253
93. Traskman L., Asberg M., Bertilsson L., Sjostrand L. Monoamine metabolites in CSF and suicidal behavior. Archives of General Psychiatry 1981; 38: 631 – 636
94. Van Praag H. M. CSF-5HIAA and suicide in non-depressed schizophrenics. Lancet 1983; 1: 977 – 978
95. Van Praag H. M. Serotonergic dysfunction and aggression control. Psychological Medicine 1991; 21: 15 – 19
96. Wainerdi H. R. Does the multiple-sclerosis syndrome begin at puberty?. Boston Medical Quarterly 1961; 12: 44 – 47
97. White R. F. Emotional and cognitive correlates of multiple sclerosis. Journal of Neuropsychiatry 1990; 2: 422 – 428
98. Whitlock F. A., Siskind M. M. Depression as a major symptom of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 1980; 43: 861 – 865
99. Yehuda R., Southwick S. M., Ostroff R. B., Mason J. W., Giller E. Neuroendocrine aspects of suicidal behavior. Neurologic Clinics 1988; 6: 83 – 102
100. Zeldow P. B., Pavlou M. Physical disability, life stress, and psychosocial adjustment in multiple sclerosis. Journal of Nervous and Mental Disease 1984; 172: 80 – 84
101. Zimmermann R. C., McDougle C. J., Schumacher M., Olcese J., Mason J. W., Heninger G. R., Price L. H. Effects of acute tryptophan depletion on nocturnal melatonin secretion in humans. Journal of Clinical Endocrinology and Metabolism 1993; 76: 1160 – 1164